Hemostemix Inc. (HEM.V)
CAD 0.1
(26.67%)
CAD 0.1
(26.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.16 Million CAD | 4.41% |
| 2022 | 3.99 Million CAD | 216.08% |
| 2021 | 1.26 Million CAD | 1621.82% |
| 2020 | -82.95 Thousand CAD | -104.07% |
| 2019 | 2.04 Million CAD | 238.69% |
| 2018 | -1.47 Million CAD | 62.84% |
| 2017 | -3.95 Million CAD | -391.87% |
| 2016 | 1.35 Million CAD | 367.74% |
| 2015 | -506.58 Thousand CAD | 84.67% |
| 2014 | -3.3 Million CAD | -841.2% |
| 2013 | -351.19 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 4.51 Million CAD | 1.84% |
| 2024 Q1 | 4.43 Million CAD | 6.37% |
| 2023 FY | 4.16 Million CAD | 4.41% |
| 2023 Q2 | 4.03 Million CAD | 7.49% |
| 2023 Q1 | 3.74 Million CAD | -6.02% |
| 2023 Q4 | 4.16 Million CAD | 6.46% |
| 2023 Q3 | 3.91 Million CAD | -2.92% |
| 2022 Q1 | 475.74 Thousand CAD | -62.31% |
| 2022 FY | 3.99 Million CAD | 216.08% |
| 2022 Q2 | 1.89 Million CAD | 297.63% |
| 2022 Q3 | 1.62 Million CAD | -14.05% |
| 2022 Q4 | 3.99 Million CAD | 145.39% |
| 2021 Q3 | 798.7 Thousand CAD | 35.76% |
| 2021 Q1 | -537.87 Thousand CAD | -548.43% |
| 2021 Q2 | 588.3 Thousand CAD | 209.37% |
| 2021 FY | 1.26 Million CAD | 1621.82% |
| 2021 Q4 | 1.26 Million CAD | 58.05% |
| 2020 Q2 | -409.85 Thousand CAD | -138.62% |
| 2020 Q3 | -70.17 Thousand CAD | 82.88% |
| 2020 Q4 | -82.95 Thousand CAD | -18.21% |
| 2020 Q1 | -171.76 Thousand CAD | -108.42% |
| 2020 FY | -82.95 Thousand CAD | -104.07% |
| 2019 Q4 | 2.04 Million CAD | 16.96% |
| 2019 FY | 2.04 Million CAD | 238.69% |
| 2019 Q3 | 1.74 Million CAD | 297.83% |
| 2019 Q2 | 438.48 Thousand CAD | 169.76% |
| 2019 Q1 | -628.51 Thousand CAD | 57.27% |
| 2018 FY | -1.47 Million CAD | 62.84% |
| 2018 Q4 | -1.47 Million CAD | 43.45% |
| 2018 Q3 | -2.6 Million CAD | 32.67% |
| 2018 Q2 | -3.86 Million CAD | 21.76% |
| 2018 Q1 | -4.93 Million CAD | -24.72% |
| 2017 Q1 | 892.73 Thousand CAD | -34.18% |
| 2017 Q2 | 1.23 Million CAD | 38.48% |
| 2017 Q3 | -5.55 Million CAD | -549.42% |
| 2017 Q4 | -3.95 Million CAD | 28.75% |
| 2017 FY | -3.95 Million CAD | -391.87% |
| 2016 Q4 | 1.35 Million CAD | 12.36% |
| 2016 FY | 1.35 Million CAD | 367.74% |
| 2016 Q1 | 162.3 Thousand CAD | 132.04% |
| 2016 Q2 | 332.73 Thousand CAD | 105.0% |
| 2016 Q3 | 1.2 Million CAD | 262.79% |
| 2015 Q1 | -2.59 Million CAD | 21.47% |
| 2015 Q4 | -506.58 Thousand CAD | 28.42% |
| 2015 Q3 | -707.75 Thousand CAD | 59.49% |
| 2015 Q2 | -1.74 Million CAD | 32.69% |
| 2015 FY | -506.58 Thousand CAD | 84.67% |
| 2014 Q2 | -171.87 Thousand CAD | 5.76% |
| 2014 Q1 | -182.38 Thousand CAD | 10.19% |
| 2014 FY | -3.3 Million CAD | -841.2% |
| 2014 Q4 | -3.3 Million CAD | -3042.34% |
| 2014 Q3 | -105.19 Thousand CAD | 38.8% |
| 2013 FY | -351.19 Thousand CAD | 0.0% |
| 2013 Q2 | -243.74 Thousand CAD | 16.37% |
| 2013 Q3 | -195.56 Thousand CAD | 19.77% |
| 2013 Q4 | -203.08 Thousand CAD | -3.85% |
| 2013 Q1 | -291.45 Thousand CAD | -303.68% |
| 2012 Q4 | -72.19 Thousand CAD | 6.9% |
| 2012 Q3 | -77.55 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arch Biopartners Inc. | 4.18 Million CAD | 0.45% |
| Covalon Technologies Ltd. | -7.23 Million CAD | 157.605% |
| Universal Ibogaine Inc. | 1.01 Million CAD | -311.821% |
| Kane Biotech Inc. | 7.52 Million CAD | 44.649% |
| MedMira Inc. | 9.25 Million CAD | 55.0% |
| Marvel Biosciences Corp. | 443.37 Thousand CAD | -839.624% |
| NervGen Pharma Corp. | -11.46 Million CAD | 136.346% |
| XORTX Therapeutics Inc. | -4.53 Million CAD | 191.948% |